You are here : Home > Funding & TTO > Europe > Research & Innovation Actions ... > ABIRISK

Europe | European & international partnerships | Immune system

Anti-Biopharmaceutical Immunization: prediction and analysis of clinical relevance to minimize the RISK


ABIRISK Project aims to provide an integrated approach to anti-drug (AD) immunization, bringing together, a large network of clinicians from various specialties with broad experience in the care of patients treated with various type of biopharmaceuticals products and developing AD antibodies, biologists familiar with the immune monitoring of patients, scientists specialized in the mechanisms of immunogenicity, methodologists and biostatisticians. 

european funding:  ria (Research and Innovation Actions)

Innovative Medicines Initiative 


Published on 3 July 2012


A growing number of drugs are based on biological molecules such as proteins and monoclonal antibodies. These new drugs have led to the development of new and more effective treatments for a number of serious conditions. However, these drugs sometimes trigger a reaction from the patient's immune system, which can decrease the effectiveness of the drug or cause serious side effects.
The goal of the IMI-funded ABIRISK project is to shed new light on the factors behind this immune response. The project, which represents the first extensive and coordinated effort to address this problem, was officially launched on March 1, 2012. ABIRISK will contribute to the creation of new, safer biopharmaceuticals and will also generate tools to determine how individual patients are likely to respond, both in clinical trials and after they are on the market.

Project duration
5 years
34.9 millions €

​Number of partners

Starting date
March 01, 2012

Coordinator : GlaxoSmithKline

Joliot Institute Contact: Bernard Maillère (

website :

agreement id : 115303


IMI is the world's largest public-private partnership (PPP) in the life sciences. It is a partnership between the European Union (represented by the European Commission) and the European pharmaceutical industry (represented by EFPIA, the European Federation of Pharmaceutical Industries and Associations).

The objective of IMI, particularly in its second phase (IMI2, 2014-2020), is to develop new generation vaccines, drugs and treatments, such as new antibiotics.

For more information: